Archive · 4 Aug 2025
Epigral Aims for 10% Volume Growth in FY26
Epigral, a company, wants to increase how much it sells by 10% in a few years.
The company's boss, Maulik Patel, says they will invest in making more chemicals that are currently bought from other countries.
This expansion is to fulfill what people in their country need and to decrease how much they depend on imports.
By making more of these chemicals, they hope to sell more and be less reliant on getting them from other places.
This is part of a plan to grow the business and be more self-sufficient.
Epigral aims for 10% volume growth in fiscal year 2026.
The company plans to expand capacity for import-substitute chemicals.
The expansion aims to meet domestic demand.
This expansion also intends to lower reliance on imports.
Maulik Patel is the Chairman and Managing Director of Epigral.
- Who
- Epigral and its Chairman and Managing Director, Maulik Patel.
- What
- Epigral is targeting a 10% volume growth in fiscal year 2026 and plans to expand its capacity.
- When
- Epigral is targeting fiscal year 2026.
- Where
- Not specified.
- Why
- To meet domestic demand and lower dependence on imports.
- Company
- Epigral
- Target Growth
- 10% volume growth in FY26
- Executive
- Maulik Patel
- Role
- Chairman and Managing Director
- Strategy
- Expand capacity for import-substitute chemicals